dc.contributor.author
Remschmidt, Cornelius
dc.contributor.author
Rieck, Thorsten
dc.contributor.author
Bödeker, Birte
dc.contributor.author
Wichmann, Ole
dc.date.accessioned
2018-06-08T03:24:38Z
dc.date.available
2015-04-22T08:17:14.658Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/15105
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-19293
dc.description.abstract
Background Elderly people are at increased risk for severe influenza illness
and constitute therefore a major target-group for seasonal influenza
vaccination in most industrialized countries. The aim of this study was to
estimate influenza vaccine effectiveness (VE) among individuals aged 60+ years
over three seasons and to assess if the screening method is a suitable tool to
monitor influenza VE in this particular target-group in Germany. Methods We
identified laboratory-confirmed influenza cases aged 60+ years through the
national communicable disease reporting system for seasons 2010/11, 2011/12
and 2012/13. Vaccination coverage (VC) data were retrieved from a database of
health insurance claims representing ~85% of the total German population. We
applied the screening method to calculate influenza subtype-specific VE and
compared our results with VE estimates from other observational studies in
Europe. Results In total, 7,156 laboratory-confirmed influenza cases were
included. VE against all influenza types ranged between 49% (95% confidence
interval [CI]: 39–56) in 2011/12 and 80% (95% CI: 76-83%) in 2010/11. In
2010/11 subtype-specific VE against influenza A(H1N1)pdm and B was 76% and
84%, respectively. In the following seasons, VE against influenza A(H1N1)pdm,
A(H3N2) and B was 87%, -9% , 74% (2011/12), and 74%, 39%, 73% (2012/13). VE
was higher among hospitalized compared to non-hospitalized influenza A cases.
Seventeen observational studies from Europe reporting subtype-specific VE
among the elderly were identified for the respective seasons (all applying the
test-negative design) and showed comparable subtype-specific VE estimates.
Conclusions According to our study, influenza vaccination provided moderate
protection against laboratory-confirmed influenza A(H1N1)pdm and B in
individuals aged 60+ but no or only little protection against A(H3N2). Higher
VE among hospitalized cases might indicate higher protection against severe
influenza disease. Based on the available data, the screening method allowed
us to assess subtype-specific VE in hospitalized and non-hospitalized elderly
persons. Since controlling for several important confounders was not possible,
the applied method only provided crude VE estimates. However, given the
precise VC-data and the large number of cases, the screening method provided
results being in line with VE estimates from other observational studies in
Europe that applied a different study design.
de
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
Vaccine effectiveness
dc.subject
Screening method
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
Application of the screening method to monitor influenza vaccine effectiveness
among the elderly in Germany
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
BMC Infectious Diseases. - 15 (2015), Artikel Nr. 137
dcterms.bibliographicCitation.doi
10.1186/s12879-015-0882-3
dcterms.bibliographicCitation.url
http://www.biomedcentral.com/1471-2334/15/137
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000022250
refubium.note.author
Der Artikel wurde in einer Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000004797
dcterms.accessRights.openaire
open access